San Diego-primarily based Viking Therapeutics marked itself as a significant competitor in the weight loss drug industry in February just after revealing promising information from a mid-phase demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when offered as being a weekly injection As well as